Authorized purpose: The Biograph VK10 combines X-ray CT and PET to register and fuse anatomic and physiologic information, supports independent CT or PET imaging, and aids trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function; the CT may also support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.
Clinical role
PET, CT, or fused PET/CT acquisition and image processing to support professional diagnosis, staging, treatment planning, or organ-function assessment where labeled.
Images and patients
PET/SPECT/Nuclear Medicine · Whole body, cardiovascular, neurological, oncologic, and organ-function imaging
Key limitation
Keep in mind: Radiopharmaceutical, scan protocol, patient population, dose, and clinical-use limits remain those of the exact labeling; output does not replace clinical judgment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The Biograph VK10 combines X-ray CT and PET to register and fuse anatomic and physiologic information, supports independent CT or PET imaging, and aids trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function; the CT may also support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole body, cardiovascular, neurological, oncologic, and organ-function imaging Input: PET radiopharmaceutical distribution and CT acquisition data, with supported attenuation, registration, and protocol inputs.
Who uses it?Intended users: Appropriately trained healthcare professionals, including nuclear-medicine or radiology practitioners where stated in the exact labeling.
What does the software produce?Output: PET, CT, and fused images with quantitative or attenuation information for professional interpretation.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan protocol, patient population, dose, and clinical-use limits remain those of the exact labeling; output does not replace clinical judgment.
Clinical takeaway. Clinical role: The Biograph VK10 combines X-ray CT and PET to register and fuse anatomic and physiologic information, supports independent CT or PET imaging, and aids trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function; the CT may also support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports PET performance testing in accordance with NEMA NU 2: 2018 on the system, with listed criteria such as transverse resolution, co-registration accuracy, and lung residual error reported as Pass and all performance testing meeting predetermined acceptance values; CT subsystem performance testing was included in the original CT premarket notification, with no changes affecting it. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The Biograph VK10 combines X-ray CT and PET to register and fuse anatomic and physiologic information, supports independent CT or PET imaging, and aids trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function; the CT may also support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.
PET, CT, or fused PET/CT acquisition and image processing to support professional diagnosis, staging, treatment planning, or organ-function assessment where labeled.
Radiopharmaceutical, scan protocol, patient population, dose, and clinical-use limits remain those of the exact labeling; output does not replace clinical judgment.
The exact FDA document reports PET performance testing in accordance with NEMA NU 2: 2018 on the system, with listed criteria such as transverse resolution, co-registration accuracy, and lung residual error reported as Pass and all performance testing meeting predetermined acceptance values; CT subsystem performance testing was included in the original CT premarket notification, with no changes affecting it. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems and there have been no changes affecting this testing." … "PET Testing in accordance with NEMA NU 2: 2018 was conducted on the system.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports PET performance testing in accordance with NEMA NU 2: 2018 on the system, with listed criteria such as transverse resolution, co-registration accuracy, and lung residual error reported as Pass and all performance testing meeting predetermined acceptance values; CT subsystem performance testing was included in the original CT premarket notification, with no changes affecting it. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems and there have been no changes affecting this testing." … "PET Testing in accordance with NEMA NU 2: 2018 was conducted on the system.". Read from the exact FDA decision document on 2026-11-14.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K233677
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K233677; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K233677; a broader clinical population is not established here.
Scopeexact submission
Tested versionBiograph VK10 (K233677)
IndependenceSponsor or vendor study
K233677
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: PET radiopharmaceutical distribution and CT acquisition data, with supported attenuation, registration, and protocol inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Source context, not route validation: The exact FDA package describes Biograph VK10 as a combined PET/CT scanner system whose components include acquisition and processing workstations with associated software, with the software integrated into the system. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The Biograph PET/CT systems are combined multi-slice X-Ray Computed Tomography and Positron Emission Tomography scanners." … "Additional components of the system include a patient handling system and acquisition and processing workstations with associated software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: PET, CT, and fused images with quantitative or attenuation information for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Biograph VK10 as a combined PET/CT scanner system whose components include acquisition and processing workstations with associated software, with the software integrated into the system. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The Biograph PET/CT systems are combined multi-slice X-Ray Computed Tomography and Positron Emission Tomography scanners." … "Additional components of the system include a patient handling system and acquisition and processing workstations with associated software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
PET, CT, or fused PET/CT acquisition and image processing to support professional diagnosis, staging, treatment planning, or organ-function assessment where labeled.
exact submission · checked 2026-09-04
Submission-anchored workflow summary, not a local acceptance or deployment result.
Current vendor material is product-family context for K233677 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: The Biograph Vision.X and Biograph Vision.X Edge combine X-ray CT and PET to register and fuse anatomic and physiologic information, support independent CT or PET imaging, aid trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function, and support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, cardiovascular, neurological, oncologic, and organ-function imaging
Authorized purpose: The uMI Panvivo PET/CT system provides anatomical and functional images. PET depicts the distribution of approved radiopharmaceuticals and CT provides diagnostic tomographic and photon-attenuation information. The FDA indication describes qualified-professional use for detection, localization, evaluation, diagnosis, staging, restaging, monitoring, and follow-up in oncology, infection and inflammation, neurology, and other labeled workflows, plus radiotherapy planning, interventional radiology, and protocol-constrained low-dose lung-cancer screening.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body and regional anatomy represented in PET/CT studies
Authorized purpose: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Authorized purpose: uMI Panvivo and Panvivo S acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, and the labeled oncology, cardiology, neurology, infection, inflammation, radiotherapy-planning, and interventional workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.